Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.20.

A number of equities research analysts have commented on PYXS shares. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday. Zacks Research lowered Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday. Royal Bank Of Canada decreased their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Finally, Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 price target for the company.

Pyxis Oncology Trading Down 1.2%

Shares of NASDAQ PYXS opened at $1.61 on Tuesday. The company’s 50-day moving average price is $2.81 and its 200 day moving average price is $2.44. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55. The stock has a market cap of $100.24 million, a price-to-earnings ratio of -1.01 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, research analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in shares of Pyxis Oncology by 2,690.9% during the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares during the period. Longaeva Partners L.P. acquired a new position in Pyxis Oncology in the third quarter valued at $1,117,000. Citadel Advisors LLC purchased a new position in Pyxis Oncology during the third quarter worth about $749,000. Jane Street Group LLC acquired a new stake in Pyxis Oncology in the 2nd quarter worth about $370,000. Finally, Schulhoff & Co. Inc. boosted its stake in Pyxis Oncology by 125.4% in the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after buying an additional 153,000 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.